Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Galera Therapeutics Inc (GRTX)

Galera Therapeutics Inc (GRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,349
  • Shares Outstanding, K 54,392
  • Annual Sales, $ 0 K
  • Annual Income, $ -62,220 K
  • 60-Month Beta 2.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade GRTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.89
  • Most Recent Earnings $-0.33 on 11/14/23
  • Latest Earnings Date 03/27/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 496.26% ( +496.26%)
  • Historical Volatility 143.65%
  • IV Percentile 82%
  • IV Rank 36.21%
  • IV High 1,310.72% on 08/15/23
  • IV Low 33.90% on 06/20/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 50
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 631
  • Open Int (30-Day) 1,235

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.58
  • Growth Rate Est. (year over year) +172,341.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1513 +8.79%
on 03/27/24
0.2600 -36.69%
on 02/29/24
-0.1010 (-38.03%)
since 02/28/24
3-Month
0.1366 +20.50%
on 12/29/23
0.2900 -43.24%
on 02/28/24
+0.0216 (+15.10%)
since 12/28/23
52-Week
0.0853 +92.97%
on 10/31/23
3.5900 -95.42%
on 06/13/23
-2.4454 (-93.69%)
since 03/28/23

Most Recent Stories

More News
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American...

GRTX : 0.1646 (+7.23%)
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC

Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the...

GRTX : 0.1646 (+7.23%)
Galera to Present at Jefferies Healthcare Conference

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 0.1646 (+7.23%)
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and...

GRTX : 0.1646 (+7.23%)
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates

Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 ...

GRTX : 0.1646 (+7.23%)
Galera Announces Plan to Submit Avasopasem NDA by Year End

After discussions with FDA, Company is on track to file an NDA for avasopasem for the treatment of radiotherapy-induced severe oral mucositis by end of...

GRTX : 0.1646 (+7.23%)
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on...

GRTX : 0.1646 (+7.23%)
Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug Study

Editas (EDIT) doses the first patient pediatric patient in the BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10).

VYGR : 9.56 (-4.59%)
EDIT : 7.36 (-1.08%)
APLT : 6.85 (unch)
GRTX : 0.1646 (+7.23%)
Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.

VYGR : 9.56 (-4.59%)
APTX : 0.0960 (+3.11%)
APLT : 6.85 (unch)
GRTX : 0.1646 (+7.23%)
Bristol Myers (BMY) Gets EC Nod for CAR T Cell Therapy Breyanzi

The European Commission grants marketing authorization to Bristol Myers' (BMY) Breyanzi for treating certain forms of relapsed or refractory large b-cell lymphoma.

BMY : 53.25 (unch)
VYGR : 9.56 (-4.59%)
APLT : 6.85 (unch)
GRTX : 0.1646 (+7.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel, proprietary therapeutics to transform radiotherapy in cancer. The company's product candidate is GC4419, a highly selective and potent small molecule dismutase mimetic which...

See More

Key Turning Points

3rd Resistance Point 0.2004
2nd Resistance Point 0.1902
1st Resistance Point 0.1718
Last Price 0.1646
1st Support Level 0.1432
2nd Support Level 0.1330
3rd Support Level 0.1146

See More

52-Week High 3.5900
Fibonacci 61.8% 2.2512
Fibonacci 50% 1.8376
Fibonacci 38.2% 1.4241
Last Price 0.1646
52-Week Low 0.0853

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar